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Abstract
Introduction: Asthmatic inflammation is responsible for vital features of the disease, including bronchial hyperresponsiveness
(BHR). At present we do not have precise markers for monitoring asthmatic inflammation. C-reactive protein (CRP),
a marker of systemic inflammation, seemed to be a factor which could also reflect the level of asthmatic inflammation
expressed by BHR. Therefore the relationship between CRP concentration and BHR was evaluated.
Materials and Methods: One hundred and two patients entered the study. A skin prick test with a broad spectrum of common
aeroallergens as well as baseline spirometry and a histamine bronchoprovocation test were performed in each subject. Blood
samples for high-sensitivity CRP (hsCRP) measurement were taken before the bronchial challenge tests.
Results: Serum hsCRP concentrations ranged from 0.20 to 14.5 mg/l (median: 1.2 mg/l, 25–75% quartiles: 0.6–2.4). Positive
skin prick tests were found in 26 subjects. Bronchial hyperresponsiveness was confirmed in 42 patients (first subgroup), while
60 subjects did not demonstrate BHR (second subgroup). Among the patients with BHR, asthma was diagnosed in 33 cases
and Corrao syndrome in 9. In both subgroups, serum hsCRP concentrations had similar levels (median: 1.4 mg/l, 25–75%
quartiles: 0.8–2.4 and median: 0.9 mg/l, 25–75% quartiles: 0.5–2.8, respectively; p=0.297). There was no statistically signifi-
cant correlation (r= –0.163, p=0.302) between serum hsCRP concentration and the level of BHR expressed as the 20%
provocative concentration for histamine. In addition, hsCRP serum concentration, after adjustment for age, atopy, body
mass index, and gender, was not a significant predictor of positive histamine bronchoprovocation test results (p=0.22,
OR=0.86, 95% CI).
Conclusions: Serum hsCRP concentration is not a good marker of BHR, which is mainly dependent on asthmatic inflamma-
tion and is measured during bronchial challenge with histamine. This finding is important for interpreting and discussing
results obtained from epidemiological and population-based studies on relationships between either CRP concentration and
BHR or local and systemic inflammation.
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INTRODUCTION
Bronchial hyperresponsiveness (BHR) is a crucial
attribute of asthma. It is due to chronic asthmatic inflam-
mation and may reflect the level of the inflammatory
process [16]. Direct airway challenge with histamine or
metacholine discloses BHR, expressed as the 20%
provocative concentration (PC20) value, and is also used
for assessing the potential anti-inflammatory effects of
treatment with new agents. However, using PC20 for his-
tamine which reflects the BHR level, though priceless in
the diagnosis of asthma, is not valuable in monitoring
asthmatic inflammation. Airway challenge with hista-
mine is accompanied by discomfort to the patient and
sometimes produces life-threatening situations; more-
over, it is expensive and time consuming for medical
staff. Other means of assessing airway inflammation in
asthma, such as the evaluation of many markers in
induced sputum (cytokines, eosinophils) [6, 22], bron-
choalveolar lavage [5, 10], or exhaled air (NO, CO) [13,
16, 18], share the same inconveniences as the determi-
nation of BHR. On the other hand, convincing data
show that bronchial asthma treatment developed on the
basis of inflammatory premises is more effective than
treatment which considers the classical British Thoracic
Society recommendations [6].
Recent publications suggest that C-reactive protein
(CRP) could be taken into consideration as a simple,
cheap, and reliable marker for monitoring asthmatic
inflammation [8, 9, 17]. If this hypothesis was true,
there should be a noticeable interrelationship between
CRP and some BHR indices such as direct airway chal-
lenges results. Theoretically, CRP should not exist in
a healthy organism, but even minimal exciting factors
including age, body mass index (BMI), gender, smoking
and variability of blood pressure in normotensive
patients may either trigger or bias trace amount of CRP
production [1]. Therefore, a CRP concentration of <5
mg/l is accepted as the normal value. The normal medi-
an concentration of CRP is 0.8 mg/l, with 90% of appar-
ently healthy individuals having a value less than 3
mg/l and 99% less than 12 mg/l. It is produced by the
liver at a higher concentration when the organism is
challenged by a significant inflammatory stimulus, such
as endotoxins from the membranes of Gram-negative
bacteria inhaled into the bronchial tree of asthmatic
patients [14]. It is well known that CRP increases dur-
ing infection and autoimmune disturbances [20]. Much
attention has been focused lately on CRP in cardiovas-
cular diseases, such as chronic heart failure [26],
ischemic heart disease [12], arrhythmia [2], and athero-
sclerosis [27]. Especially interesting are publications
pointing to CRP as a marker which may have prognos-
tic value in ischemic heart attack [3] and irregularity of
rhythm [11]. 
The main question concerns the relationships
between local asthmatic inflammation, mediated by Th2
CD4+ lymphocytes, and systemic inflammation, which
depends on Th1 CD4+ lymphocytes. At present, very lit-
tle is known about this, but it must be realized that such
relationships, even complex ones, exist and one segment
of the immune response influences another, also result-
ing in CRP production [25]. Interesting experimental
data suggest that CRP may inhibit local inflammatory
effects and also protect against Th2-mediated reactions
[21]. Being aware of these relationships, as well as the
circumstances, we developed this study using a purely
clinical model to determine whether CRP may be
a marker of asthmatic inflammation, expressed by BHR,
and thus be useful in monitoring this process and pre-
dicting asthma severity and exacerbation.
MATERIALS AND METHODS
Study participants
The study group consisted of 102 patients, 29 male
and 73 female aged 16–74 years (average: 38.9±14.8
years), who were admitted to our department with the
suspicion of asthma or Corrao syndrome. All subjects
enrolled in the study were free of any medication for at
least two weeks before the trial and were steroid naive
and nonsmokers. Precise clinical evaluation allowed
exclusion of chronic inflammatory and systemic dis-
eases, particularly those of pulmonary, cardiovascular,
or autoimmune origin. Anamnesis and detailed physical
examination did not reveal any abnormalities, and par-
ticularly blood pressure and heart rate were within the
normal ranges. X-ray images of the nasal sinuses and
chest as well as computed tomography, performed in
some cases, did not display changes in the upper and
lower airways and lungs. Any uncertainty in a diagnosis
was explained by means of bronchoscopy. Electro-
cardiography tracings and echocardiography did not
demonstrate heart rhythm disturbances, heart failure, or
pulmonary hypertension. There were no disturbances in
erythrocyte sedimentation rate, blood cell count, the
concentrations of glucose, uric acid, or blood lipids, and
the partial pressure of blood gases. In particular cases,
serologic evaluation was undertaken to evaluate
rheumatoid factor and anti-DNA antibodies, which
were negative. Detailed demographic data and spiro-
metric values are shown in Table 1. The study was
approved by the local ethics committee (Wroc³aw
Medical University, decision No. KB-396/2005).
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Table 1. Demographic data, spirometric values, and hsCRP serum concentrations in the entire sample and subgroups with and
without BHR
Age Male/ Weight Height FVC FEV1 BMI
CRP PC20

















Demographic data, 38.9±14.8 29/73 70.7±13.6 166.6±10.2 102.0±13.1 102.5±14.8 25.4±4.4 1.2 7.1±6.7
spirometric, and CRP 0.6–2.4
values: entire sample 
(n=102)
Positive test result 44.8±15.6 8/34 70.2±11.0 164.2±7.9 101.0±13.3 101.3±14.6 26.1± 4.5 1.4 7.1±6.7
(n=42) 0.8–2.4
Negative test result 34.8±12.8 21/39 71.1±15.3 168.3±11.2 102.7±13.1 103.3±15.0 24.9±4.3 0.9
(n=60) 0.5–2.8
p=0.0006* p=0.125** p=0.769* p=0.047* p=0.526* p=0.503* p=0.184* p=0.297***
* Calculated by Student’s t-test, ** calculated by

χ-squared-test, *** calculated by Mann-Withney U-test.
χ

– Arithmetic mean, SD – standard deviation, Me – median, 25–75% quartiles.
Study design
In each subject a skin prick test with a broad spec-
trum of common aeroallergens as well as baseline
spirometry and a histamine bronchoprovocation test
were performed. Blood samples for high-sensitivity
CRP (hsCRP) measurement were taken from the sub-
jects before the challenge test with histamine. For mea-
surements of pulmonary functions, an Alfa spirometer
(Vitalograf) was used. Each spirometric parameter was
recorded in triplicate and the best value of the lung
function test was taken for further analysis. ACCS crite-
ria were used for estimating predicted values. BHR was
determined by the histamine bronchoprovocation test
according to the European Respiratory Society guide-
lines [19]. The tidal breathing method was used.
Histamine was administered through a deVilbis nebuliz-
er in progressive concentrations of 0.125, 0.250, 0.5, 1, 2,
4, 8, and 16 mg/ml. The test was stopped when FEV1
had fallen by 20% or more. A positive histamine test was
defined as a decrease in FEV1 of at least 20%, and then
the results were expressed as the PC20. Serum hsCRP
concentrations were determined by an immunoturbidi-
metric assay with amplification of latex molecules on an
Integra 400 analyzer (Roche).
Statistical analysis
Data were statistically analyzed with Statistica soft-
ware version 6.0 (SN:AXXP412B401322AR14). To
compare factors between groups, the Student’s t-test,
the Mann-Whitney test, and the χ-squared test were
used. The interrelationship between serum hsCRP con-
centrations and PC20 values was assessed by Spear-
man’s rank correlation coefficient; p values <0.05 were
considered significant.
RESULTS
Serum CRP concentrations in the entire sample
ranged from 0.20 to 14.5 mg/l, (median: 1.2 mg/l,
25–75% quartiles: 0.6–2.4; Table 1). Positive skin-prick
tests with allergen expressing one of the features of
atopy were found in 26 subjects. 
Among the 102 participants, 42 had positive hista-
mine bronchoprovocation test results (first subgroup)
and 60 patients (second subgroup) did not present BHR
(Table 1). Among the patients with BHR, asthma was
diagnosed in 33 cases and its variant, characterized by
coughing (Corrao syndrome), in 9 participants of this
subgroup. There were no significant differences
between the two subgroups in both baseline spirometric
parameters and gender distribution. The patients with
BHR were significantly older than those with negative
bronchoprovocation results (44.8±15.6 and 34.8±12.8
years, respectively; p=0.0006).
In both subgroups, serum CRP concentrations were
on a similar level (median: 1.4 mg/l, 25–75% quartiles:
0.8–2.4 and median: 0.9 mg/l, 25–75% quartiles: 0.5–2.8;
p=0.297; Fig. 1). There was no statistically significant
correlation (r= –0.163, p=0.302) between serum CRP
concentration and the level of BHR, expressed as the
PC20 value (Fig. 2).
Logistic regression analysis showed that hsCRP
serum concentration after adjustment for age, atopy,
BMI, and gender cannot be considered a significant pre-
dictor of positive histamine bronchoprovocation test
results (p=0.22, OR=0.86; 95% CI).
DISCUSSION
The test data of this study definitely indicate that the
serum concentration of hsCRP is not associated with
asthmatic inflammation expressed by BHR and cannot
be taken into consideration as a marker of the local
inflammatory process in either atopic or non-atopic
asthma. Multivariate analyses showed that this result
was also independent of potential confounding factors
such as age, BMI, and gender. The validity of these
results are based on a purely clinical experiment and, to
our knowledge, this is the first such attempt to evaluate
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Fig. 1. CRP serum concentration in patients with negative (n=60)
and positive (n=42) bronchoprovocation test results.
Fig. 2. Spearman’s rank correlation between CRP serum concen-
tration and histamine PC20 value in patients with positive bron-
choprovocation test result (n=42).
the usefulness of measuring CRP concentration in mon-
itoring asthmatic inflammation. The importance of our
test data increases in light of a few very interesting pub-
lications, mainly of an epidemiological nature [17] and
population-based studies [8, 9], which could suggest the
possibility that serum CRP concentration may reflect
the level of bronchial inflammation in asthma, so it
could be a simple, cheap, and easy to perform test for
a clinical evaluation of the disease. 
Among these studies is an elegant work on a popu-
lation-based study by Kony et al. [9] which revealed an
association between a higher frequency of BHR and
higher CRP levels in study participants which could
reflect local inflammation within the bronchi. In our
study, hsCRP concentration in serum did not differ in
patients with and without BHR (Table 1, Fig. 1). In
addition, no significant correlation was found between
hsCRP and BHR (Fig. 2). All these data, seemingly con-
tradictory, may arise from a fascinating and unknown
link between local and systemic inflammation in asthma,
which was also emphasized by the authors of that article.
The methodology used in our study excluded events of
systemic inflammation in the study participants; thus we
can conclude that increasing CRP concentration does
not depend on asthmatic inflammation in this link. This
does not mean that sensitive systemic inflammation
markers other than CRP, such as serum amyloid-A and
plasma fibrinogen, could be significantly associated with
asthma prevalence, as shown in a study by Jousilahti et
al. [8]. However, the authors demonstrated these results
in a population-based study, which is a correct pattern
to show relationships between systemic inflammation
markers and asthma prevalence, but it does not seem to
be a good model to display linkage between asthmatic
and systemic inflammation.
Other interesting data were developed as a multi-
center epidemiological study by Ólafsdottir et al. [17],
who revealed that hsCRP concentration increases in
patients with non-allergic asthma, but not in allergic
asthma. The study demonstrated, however, no signifi-
cant relationships between CRP, atopy, and BHR,
which is as yet an indispensable feature of non-allergic
asthma as well. The lack of association between CRP
and BHR is in accordance with our observation; howev-
er, we did not show any significant difference when com-
paring atopic and non-atopic subjects (Table 1). An epi-
demiological study can show many valuable relation-
ships concerning hsCRP concentration and respiratory
symptoms, non-allergic asthma, and atopy, but under
these circumstances, that many clinical and inflammato-
ry factors may change the natural history of asthma.
Besides BMI, smoking, age, and gender, these relation-
ships may arise from atherosclerosis [27], many cardio-
vascular abnormalities [2, 12, 26], or hidden inflamma-
tory processes which may coexist with asthma in a pop-
ulation-based study. Non-allergic asthma, which has the
same immune pathological basis as the allergic type of
the disease, substantially differs from allergic asthma at
the origin of the inflammatory process [15], which prob-
ably depends on bacteria [7], viral infection [24],
unknown allergen [4], or auto-allergen [23]. Systemic
inflammation could thus be a reason for the CRP con-
centration increase in non-allergic asthma.
The study by Szalai et al. [21] was of special interest
to us as it suggested that an increase in CRP concentra-
tion may accompany the acute phase of allergic inflam-
mation. This phenomenon may occur as a secondary
reaction connected with a CRP ability to stimulate the
expression of anti-inflammatory cytokine-10, which
down-regulates the activity of the Th2 lymphocyte popu-
lation. This observation may be an inspiration to devel-
op a study on the significance of CRP concentration as
a marker of allergic asthma exacerbation. Our study
results clearly showed that hsCRP serum concentration
in asthma did not correlate with BHR which, in turn,
indirectly suggests its poor relationship with asthmatic
inflammation. It should also be underlined that all our
patients represented a subpopulation of newly diag-
nosed asthma without any significant concomitant dis-
eases. Therefore we speculate that the increase in CRP
concentration reported among a proportion of asthmat-
ics in epidemiological and population-based studies
might result from other conditions coexisting with
chronic asthma.
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